2023
Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials
Balasubramanian P, Kernan W, Sheth K, Ofstad A, Rosenstock J, Wanner C, Zinman B, Mattheus M, Marx N, Inzucchi S. Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials. Stroke 2023, 54: 2013-2021. PMID: 37449424, PMCID: PMC10358436, DOI: 10.1161/strokeaha.122.042053.Peer-Reviewed Original ResearchConceptsCardiovascular risk factor controlRisk factor controlCoronary artery diseaseEMPA-REG OUTCOMECardiovascular outcome trialsType 2 diabetesRisk factorsOutcome trialsBlood pressureOdds ratioAntiplatelet/anticoagulant medicationsAntiplatelet/anticoagulant therapyDiabetes cardiovascular outcome trialsSuboptimal risk factor controlCardiovascular risk factorsRecurrent ischemic eventsDiastolic blood pressureSystolic blood pressureRespective odds ratiosFactor controlCross-sectional analysisLogistic regression modelsMacrovascular complicationsStatin useAnticoagulant medication
2000
Phenylpropanolamine and the Risk of Hemorrhagic Stroke
Kernan W, Viscoli C, Brass L, Broderick J, Brott T, Feldmann E, Morgenstern L, Wilterdink J, Horwitz R. Phenylpropanolamine and the Risk of Hemorrhagic Stroke. New England Journal Of Medicine 2000, 343: 1826-1832. PMID: 11117973, DOI: 10.1056/nejm200012213432501.Peer-Reviewed Original ResearchConceptsUse of coughHemorrhagic strokeAppetite suppressantsCold remediesControl subjectsOdds ratioIndependent risk factorCase-control studyYears of ageRandom digit dialingIntracerebral hemorrhageCase reportRisk factorsBrain lesionsWomen 18CoughEligibility criteriaStrokeU.S. hospitalsPhenylpropanolamineWomenPatientsMenRiskAssociation